Join us on Thursday, February 22^nd for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Thursday, February 22, 2024
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Nonmetastatic Urothelial Bladder Cancer
• Metastatic Disease

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other allied healthcare professionals involved in the treatment of urothelial bladder cancer.

Learning Objectives
At the conclusion of this activity, participants should be able to

• Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk, non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
• Evaluate available findings from clinical trials establishing the benefit of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this strategy.
• Recognize how biological and patient-specific factors influence the selection and sequencing of treatment for metastatic urothelial bladder cancer (mUBC).
• Review available evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy for newly diagnosed mUBC, and determine the current utility of these agents in clinical practice.
• Appreciate the biological rationale for and available research findings with anti-PD-1/PD-L1 antibodies combined with chemotherapy or antibody-drug conjugates as first-line treatment for mUBC, and assess the current and future role of these regimens in the care of patients.
• Recall pivotal clinical trial findings leading to the FDA approval of novel compounds, such as antibody-drug conjugates and tyrosine kinase inhibitors, for previously treated locally advanced or metastatic UBC, and identify patients for whom therapy with these approaches would be appropriate.
• Interrogate available clinical trial findings with HER2-directed therapies for advanced UBC, and evaluate the future utility of these agents for appropriately selected patients.
• Implement a plan of care to recognize and manage side effects and toxicities associated with approved and emerging systemic therapies for mUBC.
• Develop an understanding of the biological rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for patients with NMIBC, MIBC and mUBC.

CE Credit
CME and ABIM MOC credit links will be emailed to each participant within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Gupta — Advisory Committees: Acrivon Therapeutics, Bristol Myers Squibb, Merck, Seagen Inc; Consulting Agreements: Astellas, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, EMD Serono Inc, Foundation Medicine, Gilead Sciences Inc, Guardant Health, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Acrivon Therapeutics, Bristol Myers Squibb, Merck, Novartis, QED Therapeutics, Roche Laboratories Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Protara Therapeutics; Speakers Bureaus: Bristol Myers Squibb, Gilead Sciences Inc, Seagen Inc; Stock Options/Stock — Public Company: BioNTech SE, Moderna, Nektar Therapeutics. Prof Powles — Advisory Committees, Grants/Funding to Organization/Institution and Strategic Advisory Roles: Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, MSD, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Mashup Media, LLC, Merck Serono, MSD, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Seagen Inc, Bristol Myers Squibb, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.